ArticleJournal of medical genetics2021
Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors.
Article in Journal of medical genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Pooled it
- Large scale evaluation of a multiple tumor marker panel for lung cancer diagnosis and histological subtyping.Discover oncology · 2026Article
- Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer.Communications medicine · 2026Article
- Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.Journal of translational medicine · 2025Article
- Air pollution exposure modes, smoking and genetic risk with chronic respiratory diseases: a prospective study.NPJ primary care respiratory medicine · 2025Article
- Inhibitory effect of Endostar on HIF-1 with upregulation of MHC-I in lung cancer cells.Cancer biology & therapy · 2025Article
- Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial.Journal of clinical medicine · 2025Article
- [A Prospective Cohort Study on Soy Product Intake and the Risk of Lung Cancer Based on Shanghai Suburban Adult Cohort and Biobank].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- The Association between Family History of Lung Cancer and Development of Lung Cancer: Analysis from the KoGES Data in Korea.Cancers · 2024Article
- Impact of family history of cancer on development of lung cancer among the Korean population: a prospective cohort study using KoGES data.Journal of thoracic disease · 2024Article
- Significance ofInternational journal of medical sciences · 2024Article
- Health inequities across the lung cancer care continuum in ten marginalized populations: a narrative review.Journal of thoracic disease · 2023Review
- Gender disparities in lung cancer incidence in the United States during 2001-2019.Scientific reports · 2023Article
- Lung cancer in never smokers (LCINS): development of a UK national research strategy.BJC reports · 2023Review
- Article
- Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy.Pharmaceutics · 2022Review
- European lung cancer screening: valuable trial evidence for optimal practice implementation.The British journal of radiology · 2022Article
- Article
- Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Lung cancer (LC) is the most common global cancer. An individual's risk of developing LC is mediated by an array of factors, including family history of the disease. Considerable research into genetic risk factors for LC has taken place in recent years, with both low-penetrance and high-penetrance variants implicated in increasing or decreasing a person's risk of the disease. LC is the leading cause of cancer death worldwide; poor survival is driven by late onset of non-specific symptoms, resulting in late-stage diagnoses. Evidence for the efficacy of screening in detecting cancer earlier, thereby reducing lung-cancer specific mortality, is now well established. To ensure the cost-effectiveness of a screening programme and to limit the potential harms to participants, a risk threshold for screening eligibility is required. Risk prediction models (RPMs), which provide an individual's personal risk of LC over a particular period based on a large number of risk factors, may improve the selection of high-risk individuals for LC screening when compared with generalised eligibility criteria that only consider smoking history and age. No currently used RPM integrates genetic risk factors into its calculation of risk. This review provides an overview of the evidence for LC screening, screening related harms and the use of RPMs in screening cohort selection. It gives a synopsis of the known genetic risk factors for lung cancer and discusses the evidence for including them in RPMs, focusing in particular on the use of polygenic risk scores to increase the accuracy of targeted lung cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.